Genetic Technologies Limited

Equities

GTG

AU000000GTG7

Healthcare Facilities & Services

Market Closed - Australian S.E. 01:47:11 2024-04-26 am EDT 5-day change 1st Jan Change
0.12 AUD +4.35% Intraday chart for Genetic Technologies Limited -14.29% -11.11%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Genetic Technologies Raising $2 Million via ADS Offering MT
Top Midday Decliners MT
Genetic Technologies Agrees to $2 Million Equity Offering MT
Genetic Technologies Limited Establishes Precision Oncology Division CI
Genetic Technologies Launches GeneType Precision Oncology Brand, Diagnostic Tests MT
Genetic Technologies Limited Establishes Clinical Implementation Study with Breast Screen Centres Across New York, Miami and Houston CI
Genetic Technologies to Conduct Breast Cancer Integration Study in US MT
Genetic Technologies Secures Short-Term Loan from Radium Capital MT
Genetic Technologies Limited Announces the Appointment of Kathryn Andrews as Chief Financial Officer CI
Genetic Technologies Limited Announces the Appointment of Kathryn Andrews as Company Secretary CI
Genetic Technologies Limited to develop Worlds Most Advanced Comprehensive Risk Test Revolutionising Personalised Healthcare CI
Genetic Technologies Appoints CFO MT
Genetic Technologies Developing 'Most Advanced' Risk-Assessment Test for Serious Diseases; Shares Rise MT
Genetic Technologies to Work on Advanced Comprehensive Risk Test; Shares Jump 18% MT
Genetic Technologies to Launch US Advertising Campaign for Genome-Based Risk Assessment Test; Shares Surge 21% MT
Genetic Technologies Limited Reports Earnings Results for the Half Year Ended December 31, 2023 CI
Genetic Technologies Limited Announces Resignation of Nick Burrows as an Independent Non-Executive Director CI
Genetic Technologies Reports AU$3.6 Million in Q4 Cash Receipts MT
Genetic Technologies' CFO and Company Secretary Resigns; Shares Rise 3% MT
Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Chief Financial Officer CI
Genetic Technologies Limited Announces Resignation of Tony Di Pietro as Company Secretary CI
Genetic Technologies Files $75 Million Mixed Shelf MT
Top Premarket Decliners MT
Genetic Technologies Secures Nearly AU$2 Million R&D Tax Rebate for Fiscal Year 2023 MT
Transcript : Genetic Technologies Limited - Shareholder/Analyst Call
Chart Genetic Technologies Limited
More charts
Genetic Technologies Limited is an Australia-based diversified molecular diagnostics company. The Company is engaged in providing genomics-based tests on health, wellness and serious disease through its geneType and EasyDNA brands. The Company offers cancer predictive testing and assessment tools to help physicians to improve health outcomes for people around the world. The Company has a proprietary risk stratification platform that integrates clinical and genetic risk to deliver outcomes to physicians and individuals. The Company operates through three segments: EasyDNA, AffinityDNA, and GeneType / Corporate. EasyDNA segment relates to EasyDNA branded test sales and expenses. AffinityDNA segment relates to AffinityDNA branded test sales and expenses. GeneType / Corporate segment relates to geneType branded test sales and expenses, including corporate charges. The GeneType test is for breast cancer, colorectal cancer, ovarian cancer, prostate cancer, coronary artery disease and mor
More about the company
  1. Stock Market
  2. Equities
  3. GTG Stock
  4. News Genetic Technologies Limited
  5. Genetic Technologies Developing 'Most Advanced' Risk-Assessment Test for Serious Diseases; Shares Rise